Open AccessP942: DREAMM‐9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT‐INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA
Author(s) -
Usmani S. Z.,
Mielnik M.,
Koh Y.,
Alonso Alonso A.,
Leleu X.,
Quach H.,
Min C.K.,
Janowski W.,
Abdallah A.O.,
Garg M.,
Sandhu I.,
Ocio San Miguel E. M.,
Oriol A.,
RodriquezOtero P.,
Ramasamy K.,
Weisel K.,
Besemer B.,
Cavo M.,
Zhou X. L.,
Kaisermann M. C.,
Bego Marques C. M.,
Williams D.,
Carreno F.,
Kremer B. E.,
Gupta I. V.,
Hus M.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846636.06566.b4
Subject(s) - lenalidomide , tolerability , medicine , multiple myeloma , cohort , bortezomib , regimen , clinical endpoint , oncology , surgery , adverse effect , clinical trial